Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2021-09-24 Interim / Quarterly Rep…
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Rapport Financier Semestriel 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2021' (Semi-Annual Financial Report 2021) for Mauna Kea Technologies. It contains comprehensive financial statements, including consolidated accounts under IFRS, a management activity report, and an audit report for the period ending June 30, 2021. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2021
2021-09-24 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document is a press release titled 'MAUNA KEA TECHNOLOGIES REPORTS FIRST HALF 2021 FINANCIAL RESULTS'. It provides a summary of financial performance, including revenue, operating loss, and net loss for the six-month period ending June 30, 2021, along with management commentary and operational highlights. While it contains substantive financial data, it is structured as an initial earnings announcement (press release) rather than a full statutory interim report. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly/periodical financial results, which matches this document perfectly. H2 2021
2021-09-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is a press release titled 'Mauna Kea Technologies publie ses résultats du premier semestre 2021'. It provides a summary of financial results, including revenue, operating loss, and net loss for the first half of 2021, along with management commentary and post-closing highlights. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than a full, comprehensive interim report. It fits the definition of an Earnings Release (ER) as it highlights key financial performance metrics for a specific period. H1 2021
2021-09-23 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release announcing a significant capital increase (share capital increase reserved for two investors) totaling approximately €12.5 million. It details the structure of the transaction (issuance of Units consisting of shares and warrants), the parties involved (JJDC and Armistice Capital), the intended use of proceeds, dilution effects, and references regulatory filings made to the AMF (Autorité des Marchés Financiers) in France, including the approval of a listing prospectus. This content directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), but a specific announcement about raising capital.
2021-09-20 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "MAUNA KEA TECHNOLOGIES annonce une augmentation de capital d'environ 12,5 millions d'euros réservée à deux investisseurs" (MAUNA KEA TECHNOLOGIES announces a capital increase of approximately 12.5 million euros reserved for two investors). The content details the issuance of new shares (ABSA) and warrants (BSA) to specific investors, the expected gross proceeds, intended use of funds, dilution effects, and references to regulatory filings (prospectus approved by AMF). This clearly describes a corporate financing activity, specifically a capital increase/share issue. This aligns directly with the definition for 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA). Since the core subject is the mechanics and announcement of issuing new shares to raise capital, SHA is the most precise fit, although CAP is also highly relevant. Given the explicit details on share issuance ('augmentation du capital social de 454.541,8 € pour montant brut de 12.499.899,5 €'), SHA is selected as the primary classification.
2021-09-20 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Mauna Kea Technologies announcing that it has received a new 510(k) clearance from the US FDA for its Cellvizio® platform combined with fluorescein. This is a specific, material event announcement concerning regulatory approval and market access for a medical device. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a transcript (CT). Since it is a specific announcement of a regulatory milestone that is not a general regulatory filing fallback (RNS) or a legal proceeding update (LTR), it best fits under the general category of corporate news or a specific update. Given the options, this type of announcement—a significant regulatory clearance for a product—is often categorized as a general Regulatory Filing (RNS) if a more specific category like 'Product Approval' is unavailable, or sometimes grouped with Capital/Financing Updates (CAP) if it directly impacts commercialization, but RNS is the most appropriate general regulatory announcement fallback here, as it details a specific regulatory action (FDA 510(k)). However, upon reviewing the definitions, none perfectly capture a 'Regulatory Approval Announcement' for a medical device. It is a specific corporate announcement. Since it is not a financial report, management change, or shareholder action, and it is a direct communication about a regulatory event, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most suitable classification among the provided choices for this type of material, non-financial, non-management announcement.
2021-08-24 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.